Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part B Demo Concerns Unite Policy Experts Across Political Spectrum

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Democratic congressional staffers agree with Republican health policy experts there is little to like about the proposed Medicare Part B drug payment demonstration.

You may also be interested in...



Gottlieb Joins HHS Transition Team; Will Next Stop Be FDA?

Former US FDA, CMS official has been among those thought to be in the running for Trump's FDA commissioner nomination.

Romney’s Top Policy Strategist Brings Early Interest In Health Care, Part D

Lanhee Chen’s track record includes multiple national political campaigns and analysis of Part D legislation and health reform during think-tank fellowships.

Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?

A federal appeals court has upheld a lower court's determination that Medicare statutes do not allow the program to limit reimbursement for a drug under Part B to the rate for a "least costly alternative" drug

Topics

UsernamePublicRestriction

Register

PS079395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel